How to buy ImmuCell Corporation stock (ICCC)

ImmuCell Corporation is a biotechnology business based in the US. ImmuCell Corporation shares (ICCC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.58 – a decrease of 6.91% over the previous week. ImmuCell Corporation employs 75 staff and has a trailing 12-month revenue of around $23.2 million.

Our top picks for where to buy ImmuCell Corporation stock

Buy ImmuCell Corporation stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

ImmuCell Corporation stock price (NASDAQ: ICCC)

Use our graph to track the performance of ICCC stocks over time.

ImmuCell Corporation shares at a glance

• Key figures

Information last updated 2024-12-15.

Latest market close	$4.58
52-week range	$3.34 - $5.82
50-day moving average more info button	$3.61
200-day moving average more info button	$4.36
Wall St. target price	$14.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.49

Is it a good time to buy ImmuCell Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ImmuCell Corporation price performance over time

Historical closes compared with the close of $4.43 from 2024-12-18

1 week (2024-12-13)	-9.96%
1 month (2024-11-20)	23.06%
3 months (2024-09-20)	23.06%
6 months (2024-06-20)	1.84%

1 year (2023-12-20)	-7.52%
2 years (2022-12-20)	-29.91%
3 years (2021-12-20)	8.79
5 years (2019-12-20)	5.15

ImmuCell Corporation financials

Revenue TTM	$23.2 million
Gross profit TTM	$7.6 billion
Return on assets TTM	-4.87%
Return on equity TTM	-16.1%
Profit margin	-17.44%
Book value	$3.23
Market Capitalization more info button	$32.1 million

TTM: trailing 12 months

ImmuCell Corporation share dividends

We're not expecting ImmuCell Corporation to pay a dividend over the next 12 months.

Have ImmuCell Corporation's shares ever split?

ImmuCell Corporation's shares were split on a 1:100 basis on 24 July 1990 . So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ImmuCell Corporation shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for ImmuCell Corporation shares which in turn could have impacted ImmuCell Corporation's share price.

ImmuCell Corporation share price volatility

Over the last 12 months, ImmuCell Corporation's shares have ranged in value from as little as $3.34 up to $5.82. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmuCell Corporation's is 0.567. This would suggest that ImmuCell Corporation's shares are less volatile than average (for this exchange).

ImmuCell Corporation overview

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.

Frequently asked questions

null
What percentage of ImmuCell Corporation is owned by insiders or institutions?
Currently 39.524% of ImmuCell Corporation shares are held by insiders and 14.511% by institutions. How many people work for ImmuCell Corporation?
Latest data suggests 75 work at ImmuCell Corporation. When does the fiscal year end for ImmuCell Corporation?
ImmuCell Corporation's fiscal year ends in December. Where is ImmuCell Corporation based?
ImmuCell Corporation's address is: 56 Evergreen Drive, Portland, ME, United States, 04103 What is ImmuCell Corporation's ISIN number?
ImmuCell Corporation's international securities identification number is: US4525253062 What is ImmuCell Corporation's CUSIP number?
ImmuCell Corporation's Committee on Uniform Securities Identification Procedures number is: 452525306